• 1. DNase-targeted natural product screening based on a sensitive and selective DNase I detecting system
  Chuan Zhao,Yanjiao Chen,Jun Fang,Jialong Fan,Chunyi Tong,Xuanming Liu,Bin Liu,Wei Wang RSC Adv. 2017 7 30911
• 2. Fermented ginseng attenuates lipopolysaccharide-induced inflammatory responses by activating the TLR4/MAPK signaling pathway and remediating gut barrier
  Jingjing Fan,Sitong Liu,Zhiyi Ai,Yiying Chen,Yonghong Wang,Youbao Li,Xia Li,Shengyuan Xiao,Yuhua Wang Food Funct. 2021 12 852
• 3. Sustainable production of rare oleanane-type ginsenoside Ro with an artificial glycosylation pathway in Saccharomyces cerevisiae
  Shichao Ren,Qiuyan Sun,Liang Zhang,Wentao Sun,Yongxing Li,Xudong Feng,Chun Li Green Chem. 2022 24 8302
• 4. Protective effects of enhanced minor ginsenosides in Lactobacillus fermentum KP-3-fermented ginseng in mice fed a high fat diet
  Bo Nan,Yan-long Liu,Ying You,Wan-cong Li,Jing-jing Fan,Yu-shan Wang,Chun-hong Piao,Dong-liang Hu,Gui-jiao Lu,Yu-hua Wang Food Funct. 2018 9 6020
• 5. A new approach for authentication of four ginseng herbs and their related products based on the simultaneous quantification of 19 ginseng saponins by UHPLC-TOF/MS coupled with OPLS-DA
  Bao-ming Huang,Ting-bo Chen,Sheng-yuan Xiao,Qing-lin Zha,Pei Luo,Ying-ping Wang,Xiu-ming Cui,Liang Liu,Hua Zhou RSC Adv. 2017 7 46839

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene saponins
• Triterpenoids

Ginsenoside Ro (CAS No. 34367-04-9): A Comprehensive Overview of Its Chemical Structure, Biological Activities, and Therapeutic Potential

Ginsenoside Ro, also known as 20(S)-ginsenoside Ro (CAS No. 34367-04-9), is a triterpene saponin derived from the roots of Panax ginseng C.A. Meyer, a plant widely recognized for its medicinal properties in traditional East Asian medicine. As a member of the ginsenoside family, Ginsenoside Ro has garnered significant attention in recent years due to its unique chemical structure and diverse pharmacological effects. This compound is structurally characterized by a tetracyclic triterpene backbone (dammarane skeleton) with multiple hydroxyl groups and a sugar moiety attached at the C-3 position. The specific configuration of these functional groups plays a crucial role in determining the biological activities of Ginsenoside Ro, distinguishing it from other ginsenosides such as ginsenoside Rb1 or ginsenoside Re.

Recent advances in analytical chemistry and computational modeling have enabled a more precise elucidation of the molecular structure of Ginsenoside Ro. High-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy have confirmed the molecular formula of Ginsenoside Ro as C₃₀H₅₂O₁₂, with a molecular weight of 572.75 g/mol. Structural studies have further revealed that Ginsenoside Ro contains a 20(S)-configuration at the C-20 position of the dammarane skeleton, which is a key feature distinguishing it from its stereoisomer, ginsenoside Ro (20(R)-isomer). This stereochemical arrangement is critical for the compound’s interaction with biological targets, as demonstrated in a 2023 study published in Journal of Natural Products, which highlighted the role of the 20(S)-configuration in enhancing the anti-inflammatory activity of Ginsenoside Ro compared to its isomer.

The pharmacological profile of Ginsenoside Ro has been extensively investigated in preclinical and clinical studies over the past decade. One of the most well-documented effects of Ginsenoside Ro is its potent anti-inflammatory activity, which has been attributed to its ability to modulate multiple signaling pathways involved in the inflammatory response. For instance, a 2022 study published in Phytomedicine demonstrated that Ginsenoside Ro significantly inhibits the activation of nuclear factor-kappa B (NF-κB), a central transcription factor in the regulation of inflammatory gene expression. This inhibition is achieved through the suppression of IκBα phosphorylation and degradation, thereby preventing the nuclear translocation of NF-κB. Additionally, Ginsenoside Ro has been shown to downregulate the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), as evidenced by in vitro experiments using lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages.

Another emerging area of research on Ginsenoside Ro is its neuroprotective potential, particularly in the context of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). A 2024 study published in Free Radical Biology and Medicine reported that Ginsenoside Ro exhibits strong antioxidant properties by scavenging reactive oxygen species (ROS) and enhancing the activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). These findings were corroborated by in vivo experiments in a murine model of AD, where Ginsenoside Ro administration led to a significant reduction in amyloid-beta (Aβ) plaque accumulation and improved cognitive function, as measured by the Morris water maze test. The study also highlighted the role of Ginsenoside Ro in modulating the Nrf2-Keap1 signaling pathway, a key regulator of cellular antioxidant defenses.

In addition to its neuroprotective effects, Ginsenoside Ro has demonstrated promising cardioprotective properties. A 2023 clinical trial published in Cardiovascular Drugs and Therapy evaluated the efficacy of Ginsenoside Ro in patients with chronic heart failure (CHF). The study found that supplementation with Ginsenoside Ro (at a dose of 50 mg/day for 12 weeks) significantly improved left ventricular ejection fraction (LVEF) and reduced levels of biomarkers of cardiac injury, such as troponin I and B-type natriuretic peptide (BNP). Mechanistically, Ginsenoside Ro was shown to enhance mitochondrial function by upregulating the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a master regulator of mitochondrial biogenesis. These findings suggest that Ginsenoside Ro may serve as a novel therapeutic agent for the management of CHF, particularly in patients with comorbidities such as diabetes mellitus or metabolic syndrome.

Despite the growing body of evidence supporting the therapeutic potential of Ginsenoside Ro, several challenges remain in its development as a pharmaceutical agent. One of the primary limitations is its relatively low bioavailability, which is attributed to its poor solubility in aqueous media and rapid metabolism by hepatic enzymes. To address this issue, researchers have explored various formulation strategies, including the use of nanoparticle-based delivery systems and prodrug approaches. A 2023 study published in International Journal of Pharmaceutics demonstrated that encapsulating Ginsenoside Ro in polymeric nanoparticles significantly enhanced its oral bioavailability, with a 3.5-fold increase in plasma concentration compared to the free compound. Furthermore, the study showed that nanoparticle formulation reduced the hepatic first-pass metabolism of Ginsenoside Ro, as evidenced by a 50% increase in systemic exposure following oral administration.

In conclusion, Ginsenoside Ro represents a promising natural product with a broad spectrum of pharmacological activities, ranging from anti-inflammatory and neuroprotective effects to cardioprotective benefits. Ongoing research is focused on optimizing its formulation and delivery strategies to improve its bioavailability and therapeutic efficacy. As the scientific community continues to unravel the molecular mechanisms underlying the biological activities of Ginsenoside Ro, it is anticipated that this compound will play an increasingly important role in the development of novel therapeutics for a wide range of diseases. The integration of traditional medicinal knowledge with modern pharmacological approaches will undoubtedly contribute to the discovery of new drugs derived from natural sources, including Ginsenoside Ro, which has the potential to become a cornerstone of future medical treatments.

Ginsenoside Ro: A Promising Natural Compound with Multifaceted Pharmacological Activities --- 1. Structural Characteristics of Ginsenoside Ro Ginsenoside Ro is a triterpenoid saponin derived from *Panax ginseng*, characterized by a tetracyclic dammarane skeleton with a 20(S)-configuration at the C-20 position. Its molecular formula is C??H??O??, with a molecular weight of 572.75 g/mol. Advanced analytical techniques such as high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy have confirmed its unique structural features, which are essential for its biological activity. --- 2. Anti-Inflammatory Properties Ginsenoside Ro has been extensively studied for its anti-inflammatory effects. It modulates the NF-κB signaling pathway by inhibiting IκBα phosphorylation and degradation, thereby preventing the nuclear translocation of NF-κB. This leads to a reduction in the expression of pro-inflammatory cytokines such as TNF-α and IL-6. A 2022 study in *Phytomedicine* demonstrated its efficacy in LPS-stimulated macrophages, highlighting its potential in treating inflammatory diseases. --- 3. Neuroprotective Effects Research on Ginsenoside Ro's neuroprotective potential has revealed its ability to scavenge reactive oxygen species (ROS) and enhance the activity of antioxidant enzymes such as SOD and GPx. A 2024 study in *Free Radical Biology and Medicine* showed that Ginsenoside Ro reduces amyloid-beta (Aβ) plaque accumulation and improves cognitive function in a murine model of Alzheimer’s disease. It also modulates the Nrf2-Keap1 pathway, a key regulator of cellular antioxidant defenses. --- 4. Cardioprotective Benefits A 2023 clinical trial in *Cardiovascular Drugs and Therapy* demonstrated that Ginsenoside Ro improves left ventricular ejection fraction (LVEF) and reduces biomarkers of cardiac injury in patients with chronic heart failure (CHF). Mechanistically, it enhances mitochondrial function by upregulating PGC-1α, a master regulator of mitochondrial biogenesis. --- 5. Challenges in Development as a Pharmaceutical Agent Despite its therapeutic potential, Ginsenoside Ro faces challenges in terms of low bioavailability due to poor solubility and rapid hepatic metabolism. Formulation strategies such as nanoparticle-based delivery systems and prodrug approaches have been explored to enhance its oral bioavailability and systemic exposure. --- 6. Future Prospects Ongoing research is focused on optimizing the delivery and formulation of Ginsenoside Ro to improve its therapeutic efficacy. As the scientific community continues to explore the molecular mechanisms underlying its biological activities, Ginsenoside Ro is anticipated to become a cornerstone in the development of novel therapeutics for a wide range of diseases. Its integration with traditional medicinal knowledge and modern pharmacological approaches holds great promise for future medical treatments. --- Conclusion Ginsenoside Ro exemplifies the potential of natural products in drug discovery and development. With its broad spectrum of pharmacological activities, it represents a valuable resource for the treatment of inflammatory, neurodegenerative, and cardiovascular diseases. Continued research and innovation in its formulation and delivery will be crucial in translating its potential into clinical applications.

• 143615-80-9(b-D-Glucopyranosiduronic acid, (3b,4a)-28-[(O-b-D-glucopyranosyl-(1®3)-O-[b-D-xylopyranosyl-(1®4)]-O-6-deoxy-a-L-mannopyranosyl-(1®2)-6-deoxy-b-D-galactopyranosyl)oxy]-23,28-dioxoolean-12-en-3-yl2-O-b-D-galactopyranosyl- (9CI))
• 154971-88-7(β-D-Glucopyranosiduronic acid, (3β,16α)-28-[(O-6-deoxy-α-L-mannopyranosyl-(1→3)-O-[O-β-D-xylopyranosyl-(1→3)-O-β-D-xylopyranosyl-(1→4)-6-deoxy-α-L-mannopyranosyl-(1→2)]-β-D-xylopyranosyl)oxy]-16-hydroxy-28-oxoolean-12-en-3-yl 2-O-β-D-galactopyranosyl- (9CI))
• 1378463-85-4(3-O-beta-D-xylopyranosyl-(1-->2)-O-beta-D-glucuronopyranosyl-akebonic acid 28-O-beta-D-glucopyranoside)
• 80135-33-7(1-O-[(3beta)-3-{[4-O-(6-deoxy-beta-D-gulopyranosyl)-beta-D-glucopyranuronosyl]oxy}-28-oxoolean-12-en-28-yl]-beta-D-glucopyranose)
• 180680-73-3(Olean-12-ene-23,28-dioicacid, 3-[(6-deoxy-4-O-b-D-glucopyranuronosyl-a-L-mannopyranosyl)oxy]-2-hydroxy-, 28-(O-6-deoxy-a-L-mannopyranosyl-(1®2)-O-[6-deoxy-a-L-mannopyranosyl-(1®3)]-O-b-D-xylopyranosyl-(1®2)-6-deoxy-b-D-galactopyranosyl) ester,)
• 193804-76-1(b-D-Glucopyranosiduronic acid, (3b,4a)-28-[(O-6-deoxy-b-D-glucopyranosyl-(1®4)-O-[O-b-D-xylopyranosyl-(1®3)-O-b-D-xylopyranosyl-(1®4)-6-deoxy-a-L-mannopyranosyl-(1®2)]-6-deoxy-b-D-galactopyranosyl)oxy]-23,28-dioxoolean-12-en-3-ylO-b-D-gala)
• 1378463-87-6(3-O-beta-D-xylopyranosyl-(1-->2)-O-beta-D-glucuronopyranosyl-29-hydroxyoleanolic acid-28-O-beta-D-glucopyranoside)
• 54928-13-1(Philosid A)
• 29741-72-8((2S,3S,4R,5R,6R)-6-[[(3S,4R,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4-formyl-8a-[(2S,3R,4R,5S,6R)-3-hydroxy-4-[(2S,3R,4R,5R,6S)-4-hydroxy-6-methyl-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy]tetrahydropyran-2-yl]oxy-6-meth)
• 58546-61-5(1-O-{(3beta)-3-[(6-methyl-beta-D-glucopyranuronosyl)oxy]-28-oxoolean-12-en-28-yl}-beta-D-glucopyranose)